Comparative Effectiveness of Sequential Romosozumab-Denosumab vs. Denosumab Alone on Fracture Risk: A Target Trial Emulation Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1562; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Romo followed by dmab may not significantly reduce 3-year fracture risk compared with dmab alone in a broad Medicare population, but patients at higher fracture risk, particularly those with prior fracture, may have incremental benefit. Further studies should evaluate other sequential treatment strategies and examine fracture-site-specific outcomes among patients with different fracture risks."
HEOR • Alzheimer's Disease • CNS Disorders • Dementia • Musculoskeletal Diseases • Orthopedics • Rare Diseases
|
|
Ye Liu1; Hongke Wu1; Tarun Arora2; Jeffrey Curtis3
|